Aftermath of Trump's Pharma Policy: How Swiss SMEs are Affected by Drug Price Discussions

The UK government has recently committed to paying higher prices for new medicines in exchange for duty-free access for its own products. This is not an isolated footnote. Rather, it's a direct echo of American pharmaceutical policy, which is increasingly putting pressure on Swiss SMEs as well. Anyone who believes that trade flows between Washington and London have no relevance for a medical technology supplier in Thurgau or a Basel-based biotech startup is gravely mistaken.

The USA, under the previous administration, pursued a clear line: "America First" was also the motto for medicines. The goal was and is to bring production back into the country. We feel this directly here in Switzerland, the land of innovation and precision medicine. Negotiations on new free trade agreements reveal how strongly the global discussion on drug pricing is influencing our export markets and, consequently, the future of many Swiss SMEs.

How do the new US pharmaceutical tariffs affect Swiss SMEs exporting to the USA?

The impact is significant and multifaceted, even with Switzerland having negotiated a reduced tariff rate.

A baseline tariff of 100% on imported patented pharmaceuticals is a clear signal from Washington. It aims to massively boost production in the USA and disadvantage foreign suppliers. While Switzerland managed to negotiate a reduced tariff rate of 15% for its pharmaceutical imports into the USA, which appears to be a success at first glance, this figure masks a deeper dynamic that also affects our SMEs.

The 15% is a compromise, but it doesn't eliminate the fundamental pressure for an onshoring strategy. Many Swiss SMEs in the pharmaceutical sector – whether specialized active ingredient manufacturers, medical technology suppliers, or clinical trial service providers – are heavily reliant on the US market. Even a reduced tariff means additional costs, which must either erode profit margins or be passed on to customers. Both weaken competitiveness against local US providers. A company supplying highly specialized components for pharmaceutical production facilities, for example, suddenly faces higher import costs, making its end products more expensive in the USA.

The psychological effect of US policy is equally relevant. The message is clear: the USA wants fewer imports. This leads to an increased preference among American buyers for local suppliers, even if the quality or price advantage of a Swiss product would be superior. For small and medium-sized enterprises that lack the resources of global corporations to set up production facilities in the USA, this is an existential problem. They cannot simply relocate their factories.

Furthermore, this policy influences global pricing negotiations. When the USA, the world's largest pharmaceutical market, pushes for lower import prices or a relocation of production, it has domino effects. Other countries may make similar demands or try to protect their own industries. The Swiss pharmaceutical industry, often represented by associations like Interpharma, is already expressing concerns that medicines will become more expensive for patients or may not even reach the market if the framework conditions become too unfavorable.

For SMEs, this means they must fundamentally rethink their export strategies and pricing models. It's no longer just about offering a high-quality product, but also about navigating complex geopolitical and trade policy hurdles. This requires an agility that many smaller businesses have yet to develop.

What strategies can Swiss SMEs pursue to safeguard themselves against the repercussions of US pharmaceutical policy?

Diversification, a resilient supply chain, and the strategic use of data and AI are crucial for minimizing risks and seizing new opportunities.

The days when Swiss SMEs could rely solely on established export markets are over. Current US pharmaceutical policy necessitates a rethink. One of the primary strategies must be diversification. This means opening up new markets outside the USA or strengthening existing relationships in other regions such as Asia, South America, or within Europe. This spreads the risk and makes a company less vulnerable to the protectionist measures of individual countries. However, it requires detailed market analyses and adjustments to local regulatory frameworks.

In parallel, reviewing and strengthening supply chains is essential. Many SMEs are integrated into global value chains and source intermediate products or services from various countries. A one-sided dependency on individual suppliers or regions can quickly become a problem in times of political tensions or trade barriers. The strategy should aim to regionalize supply chains, implement dual sourcing, or produce critical components locally. While this may increase costs in the short term, it offers greater security and resilience against external shocks in the long run. An SME requiring highly specialized chemicals for drug production, for instance, should investigate whether it can source them from two independent suppliers in different geographical regions.

An often underestimated but increasingly important lever is the strategic use of data and Artificial Intelligence (AI). As Lukas Huber, who is deeply involved in the application of AI in business contexts, I see enormous potential here. AI-powered analyses can help sift through global trade data, anticipate political trends, and identify potential risk factors in the supply chain early on. A system could, for example, analyze news articles, trade agreements, and tariff data to generate forecasts about future market changes or trade restrictions. This gives SMEs the opportunity to act more proactively rather than just reacting to changes.

Why are negotiations on patent protection and drug prices so crucial for Switzerland and its SMEs?

They are the foundation for innovation and access to new therapies, directly impacting the competitiveness of the entire Swiss pharmaceutical industry and, consequently, that of SMEs.

Switzerland is renowned worldwide for its research-based pharmaceutical industry. This reputation, and the associated jobs and value creation, are significantly based on strong patent protection. Patents are the engine of innovation: they guarantee companies that invest enormous sums in research and development exclusivity for their discoveries. Without this protection, there would be little incentive to invest billions in developing new drugs, only a fraction of which ever reach the market.

The discussions surrounding drug prices and patent protection, as described by the NZZ in the context of the UK's negotiations with the USA, are of existential importance for Switzerland. Great Britain has committed to accepting higher prices for new medicines in exchange for duty-free access for its products. This is a direct reflection of US demands for fairer burden-sharing or, indeed, onshoring. For Switzerland, which is also striving for patent protection for pharmaceutical companies in its free trade agreements, this sets a precedent.

If patent protection is weakened or drug prices are suppressed too much by political intervention, it has direct consequences for innovation capacity. Researchers would have less incentive to stay in or develop in Switzerland. This affects not only large pharmaceutical companies but also the countless SMEs that form the ecosystem of the Swiss pharmaceutical industry as suppliers, service providers, or specialized biotech startups. Weaker patent protection or forced price reductions could lead to fewer new drugs being developed or them not reaching the Swiss or European markets at all because the investment is no longer worthwhile.

Switzerland has a strong interest in remaining an attractive location for research and development. Stable and reliable framework conditions, including robust patent protection and fair drug prices, are essential for this. If these foundations erode, it threatens not only lower investments but also the loss of highly qualified jobs and the outflow of know-how. Negotiations with the USA are therefore not merely a diplomatic matter but a direct economic policy decision for the future of the Swiss innovation landscape.

The aftermath of Trump's pharmaceutical policy is not a temporary phenomenon but has initiated a fundamental shift in the global landscape of drug pricing and production. Swiss SMEs are directly affected, even if they are not at the center of major political negotiations. The 15 percent tariffs are a compromise, but the pressure for production relocation and the debate around patent protection and drug prices persist. It's time to act proactively.

Those who do not act now risk falling behind. The future belongs to companies that not only deliver excellent products but also understand geopolitical currents and can strategically adapt to them. This means opening up new markets, strengthening supply chains, and utilizing intelligent technologies like AI to make informed decisions and enhance their own resilience.

✅ Global politics directly influence local businesses and require strategic adjustments.

✅ Proactive strategies such as market diversification and resilient supply chains are essential.

✅ Technology, particularly Artificial Intelligence, is key to analyzing risks and securing competitiveness.

Facing similar strategic challenges? Want to know how AI can make your business more resilient? Contact us for a no-obligation initial assessment of your options.